Table 4 Dysregulation of PTENP1 in clinical samples

Acute leukemia

138 AL patients and 15 healthy controls

Downregulated

[10]

Bladder cancer

Plasma samples from 50 patients with bladder cancer and 60 normal subjects

20 pairs of tumor tissues and ANTs

Downregulated

High clinical grade

[11]

60 pairs of tumor tissues and ANTs

Upregulation of miR-20a (a target of PTENP1)

[12]

Breast cancer

52 pairs of tumor tissues and ANTs

Downregulated

Poorer OS

Advanced BC stages

[13]

65 pairs of tumor tissues and ANTs

Downregulated

[14]

20 pairs of tumor tissues and ANTs

Downregulated

[16]

Cervical cancer

54 pairs of tumor tissues and ANTs

Downregulated

FIGO stage and the lymph node metastasis

[17]

88 pairs of tumor tissues and ANTs

Downregulated

Poorer OS

Advanced stage, FIGO stage, tumor size and lymph node metastasis

[18]

56 pairs of tumor tissues and ANTs

Downregulated

Poorer OS

Advanced FIGO stage, metastasis and recurrence

[19]

Endometrioid endometrial carcinoma

40 pairs of tumor tissues and ANTs

GEO database and TGCA database

Downregulated

[20]

Esophageal carcinoma

GEO database (GSE20347): 17 pairs of tumor tissues and ANTs

Downregulated

[21]

93 ESCC patients

Downregulated

Poorer OS

TNM stage and PTENP1 expression were found to be independent factors that influence the OS of patients after radical esophagectomy.

Histological grade, more advanced TNM stage, deep infiltration depth, and lymph node metastasis

Gastric cancer

768 GC patients and 768 healthy controls

Downregulated

Patients who had rs7853346 G allele showed a remarkably decreased risk of GC in comparison with those carrying C allele.

Samples with rs7853346 CG/GG genotype showed high PTENP1 mRNA expression levels than those with CC genotype.

[37]

Gastric cancer

36 pairs of tumor tissues and ANTs

Downregulated

Tumor size, clinic stage and invasion depth

[22]

Glioma

23 gliomas tissue samples

Downregulated

[23]

279 glioma patients

Downregulated

Downregulated in patients carrying the CG&GG genotypes of rs7853346 compared with patients carrying the CC genotype of rs7853346

[38]

Head and neck squamous cell carcinoma

57 HNSCC tissues and 27 ANTs

Downregulated

Poorer OS or DFS

PTENP1 level was found to be an independent predictor of the OS and DFS in patients.

History of alcohol use

[25]

Hepatocellular carcinoma

48 pairs of tumor tissues and ANTs

Downregulated

Poorer OS

Tumor size and TNM stage

[27]

129 patients with HCC, 49 patients with liver cirrhosis, 27 patients with chronic HBV, and 93 normal subjects

Downregulated in HCC than in control groups

[39]

Multiple myeloma

43 multiple myeloma patients and 35 healthy controls

Upregulated

Samples with CC genotype showed higher levels of PTENP1 and TSC1 mRNA, and lower level of miR-19b compared to the CG and GG groups. G allele of rs7853346 polymorphism induces the proliferation of cancer stem cells.

[29]

Oral squamous cell carcinoma

62 pairs of tumor tissues and ANTs

Downregulated

Poorer OS

pT-stage and clinical stage

[30]

342 OSCC patients and 711 healthy controls

20 pairs of tumor tissues and ANTs

rs7853346 strongly reduced OSCC risk.

rs7853346 strongly decreased OSCC risk with gender, age, smoking and drinking condition adjusted.

[40]

Renal cell carcinoma

40 pairs of tumor tissues and ANTs

Downregulated

[31]

Osteoporosis

30 postmenopausal

females with osteoporosis and 15 premenopausal females with

arthritis (as controls)

Downregulated

[34]